Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chimeric-Antigen Receptor (CAR) T-Cell Therapy Using Multiple CARs and Cell Marker Profiling in High Risk and Relapsed/ Refractory B-Lineage Acute Lymphoblastic Leukaemia

NCT05038696 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05038696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05038696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chimeric-Antigen Receptor (CAR) T-Cell Therapy Using Multiple CARs and Cell Marker Profiling in High Risk and Relapsed/ Refractory B-Lineage Acute Lymphoblastic Leukaemia
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1
Overall status
Unknown status
Start date
April 28, 2021
Completion date
August 1, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car, car t-cell-related encephalopathy syndrome, lymphoblastic leukemia, lymphoblastic leukemia in children, lymphoblastic leukemia, acute adult, lymphoblastic leukemia, acute, childhood